News & Updates

Show Multimedia Only
Managing comorbidities in rheumatoid arthritis in the new decade

Managing comorbidities in rheumatoid arthritis in the new decade

03 Nov 2021 byProf. Peter Taylor; Prof. Christopher Edwards; Dr. Lian Tsui Yee

Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.

Managing comorbidities in rheumatoid arthritis in the new decade

03 Nov 2021
Add-on brivaracetam for epilepsy makes good in real-world practice

Add-on brivaracetam for epilepsy makes good in real-world practice

02 Nov 2021
Omission of parametrial boost does not compromise local control, survival in modern era

Omission of parametrial boost does not compromise local control, survival in modern era

02 Nov 2021

Leaving out the use of external beam parametrial boost (EBPB) for locally advanced cervical cancer does not seem to negatively affect local control or survival in the era of image-guided brachytherapy, results of a study have shown. This then supports a reduced need for standardized use of parametrial boost.

Omission of parametrial boost does not compromise local control, survival in modern era

02 Nov 2021
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?

Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?

02 Nov 2021 byAudrey Abella

In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.

Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?

02 Nov 2021
Antigliadin IgG spots IBS patients who benefit from gluten-free diet

Antigliadin IgG spots IBS patients who benefit from gluten-free diet

02 Nov 2021

Some patients with irritable bowel syndrome (IBS) may achieve symptom reduction, particularly diarrhoea, on a gluten-free diet, and who these patients are may be identified by using the antigliadin immunoglobulin G (IgG) as a biomarker, according to a study.

Antigliadin IgG spots IBS patients who benefit from gluten-free diet

02 Nov 2021
Bevacizumab reduces need for vitrectomy in PDR patients with vitreous haemorrhage

Bevacizumab reduces need for vitrectomy in PDR patients with vitreous haemorrhage

02 Nov 2021